Abstract:

Chimeric antigen receptor engineered T cell（CAR⁃T）is an engineered molecule that combines the recognition ability of specific tumor antigens with the powerful anti⁃tumor effect of T cells. It is currently one of the important methods of tumor treatment，especially in early clinical trials of patients with B⁃cell acute lymphoblas⁃ tic leukemia，B⁃cell lymphoma and multiple myeloma，which has shown good targeting，killing，proliferation and Persistence. However，the related adverse reactions limit its wide clinical application. Among them，cytokine re⁃ lease syndrome（CRS）and immune effector cell⁃associated neurotoxicity syndrome（ICANS）are the most serious adverse reactions，understanding the classification and management of these adverse reactions can help guide and improve the prognosis. Therefore，in this review，the pathophysiological mechanism，classification and manage⁃ ment of cytokine release syndrome and immune effector cell ⁃associated neurotoxicity syndrome caused by CAR ⁃T cell therapy are discussed，as well as optimization strategies for these adverse reactions. It aims to provide new 

Key words: